The Her2 Antibody-Drug Conjugates comprise a drug moiety, an anti-HER2 antibody and a hydrophilic self-immolative linker. The antibody in this ADC compound specifically target human epidermal growth factor receptor 2 protein (HER2), which is a member of the epidermal growth factor family that are known to play an important role in both development and oncogenesis. Therefore the HER2 ADC can be used in the treatment of breast cancer, gastric cancer and ovarian cancer.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0195CL-S(P) | Anti-Human HER2 Recombinant Antibody scFv Fragment (Anti-HER2-IgGl) | FC, Cyt | Human antibody |
TAB-0195CL-F(E) | Anti-Human HER2 Recombinant Antibody Fab Fragment (Anti-HER2-IgGl) | FC, Cyt | Human antibody |
There are currently no Customer reviews or questions for TAB-0195CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.